Global Clinical Experience with Adjuvant Oxaliplatin/5-Fluorouracil (5-Fu)-based Chemotherapy for Colon Cancer: ACCElox Registry.
J. Ji,Y. S. Park,M. Liu,J. Raafat,W. Szpak,K. Bouzid,G. H. Cornelio,B. Brenner,M. Ghosn,J. R. Zalcberg
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.e14078
IF: 45.3
2011-01-01
Journal of Clinical Oncology
Abstract:e14078 Background: The Adjuvant Colon Cancer with Eloxatin (oxaliplatin)/5-FU (ACCElox) Registry was established in 2006 to record treatment and outcome information for patients with colon cancer in the Asia-Pacific, Latin America, the Middle East and Africa. Methods: Data were collected on patient/disease characteristics, treatments, adverse events and outcomes at registry entry, before each treatment, at treatment discontinuation and 6, 12, 24 and 36 months post treatment. The primary objective was to assess how adjuvant oxaliplatin/5-FU-based regimens are used in clinical practice, versus approved regimens and the clinical-trial experience. Results: By May 2010, 1,548 evaluable patients had been recruited (1,315 [84.9%] of which were treated with FOLFOX [5-FU + leucovorin + oxaliplatin]: median age 58.2 years, range 18.2–89.2; 56.7% men; 72.7% stage III, 27.3% stage II colon cancer). The median number of cycles of FOLFOX received (based on oxaliplatin administration) was 12, which is in line with the recommended number. The median dose received of each component of the regimen over the treatment course closely reflected the recommended dose (Table). 69% (n=884) of patients receiving ≥2 cycles had a treatment delay of ≥4 days; among these, dose delays were mainly due to adverse events (43%, of which platelet, bleeding and clotting disorders=25% and white cell and reticuloendothelial disorders=65%) or personal convenience reasons (37%). The majority of patients completed the treatment course (n=985, 75%). Among those who discontinued treatment (n=328), physician/patient refusal (n=124, 38%) and adverse events (n=103, 31%) were the primary reasons. Conclusions: FOLFOX is the most common oxaliplatin/5-FU-based regimen used and appears to be applied in clinical practice in line with the approved regimen. Outcome data from this cohort will be reported at a later date. FOLFOX median (IQR) dose/cycle N (% of total, n = 1,315) Fluorouracil (mg/m2) Leucovorin (mg/m2) Oxaliplatin (mg/m2) Recommended dose/cycle — 2,400 400 85 Cycle 1 1,310 (99.6%) 2,000 400 85 4 1,238 (94.1%) 2,000 400 85 8 956 (72.7%) 2,000 400 85 12 745 (56.7%) 1,900 400 74